- Home
- PMEC vs ONCT Comparison
PMEC vs ONCT Comparison
Compare PMEC & ONCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMEC
- ONCT
- Stock Information
- Founded
- PMEC 1984
- ONCT N/A
- Country
- PMEC Singapore
- ONCT United States
- Employees
- PMEC N/A
- ONCT N/A
- Industry
- PMEC
- ONCT Biotechnology: Pharmaceutical Preparations
- Sector
- PMEC
- ONCT Health Care
- Exchange
- PMEC Nasdaq
- ONCT Nasdaq
- Market Cap
- PMEC 23.4M
- ONCT 11.0M
- IPO Year
- PMEC 2023
- ONCT N/A
- Fundamental
- Price
- PMEC $0.61
- ONCT $1.43
- Analyst Decision
- PMEC
- ONCT Buy
- Analyst Count
- PMEC 0
- ONCT 3
- Target Price
- PMEC N/A
- ONCT $10.00
- AVG Volume (30 Days)
- PMEC 64.4K
- ONCT 65.2K
- Earning Date
- PMEC 09-26-2024
- ONCT 11-07-2024
- Dividend Yield
- PMEC N/A
- ONCT N/A
- EPS Growth
- PMEC N/A
- ONCT N/A
- EPS
- PMEC N/A
- ONCT N/A
- Revenue
- PMEC $72,524,000.00
- ONCT $1,846,000.00
- Revenue This Year
- PMEC N/A
- ONCT $119.11
- Revenue Next Year
- PMEC N/A
- ONCT N/A
- P/E Ratio
- PMEC N/A
- ONCT N/A
- Revenue Growth
- PMEC 5.07
- ONCT 114.15
- 52 Week Low
- PMEC $0.49
- ONCT $1.35
- 52 Week High
- PMEC $4.18
- ONCT $13.20
- Technical
- Relative Strength Index (RSI)
- PMEC 53.28
- ONCT 16.60
- Support Level
- PMEC $0.58
- ONCT $1.46
- Resistance Level
- PMEC $0.66
- ONCT $4.43
- Average True Range (ATR)
- PMEC 0.05
- ONCT 0.36
- MACD
- PMEC 0.00
- ONCT -0.16
- Stochastic Oscillator
- PMEC 55.22
- ONCT 1.57
About PMEC Primech Holdings Ltd.
Primech Holdings Ltd is a technology-driven facilities services provider in the public and private sectors operating mainly in Singapore. The services offered by the company include Facilities services, Stewarding services, Cleaning services to offices, Cleaning services to homes, and Cleaning Supplies.
About ONCT Oncternal Therapeutics Inc.
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.